Delivery of agents using metastable liposomes
Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.
1. A dosage formulation of metastable liposomes comprising:
multilamellar metastable liposomes having a mean diameter of between one and 100 microns, inclusive, which comprise tacrolimus,
wherein the ratio of the volume enclosed by the liposomes at 25° C. relative to the volume enclosed by the liposomes following heating to a temperature that surpasses the gel-fluid phase transition of one or more lipids forming the liposomes is greater than 1.0;
wherein the tacrolimus is entrapped within the lipid forming the liposomes,
wherein the tacrolimus is present in the dosage formulation in an amount ranging from between 20 to 50 mg; and
wherein the metastable liposomes are prepared by a method comprising:
(a) dispersing the lipid forming the liposomes in a co-solvent system to create an isotropic monophasic solution;
(b) mixing the isotropic monophasic solution with the tacrolimus to form a pre-liposomal solution;
(c) lyophilizing the pre-liposomal solution to produce a pre-liposomal lyophilized formulation; and
(d) rehydrating the pre-liposomal lyophilized formulation of step (c) to produce the liposomes.
2. The formulation of claim 1 , wherein the tacrolimus is present in the dosage formulation in an amount between 10 to 20 mg.
3. The formulation of claim 1 , wherein the tacrolimus is present in the dosage formulation in an amount between 3 to 10 mg.
4. The formulation of claim 1 , wherein the tacrolimus is present in the dosage formulation in an amount between 1 to 3 mg.
5. The formulation of claim 1 , wherein the tacrolimus is present in the dosage formulation in an amount between 0.1 to 1 mg.
6. The formulation of claim 1 , further comprising a prophylactic agent, a diagnostic agent, or a second therapeutic agent encapsulated within the liposomes.
7. The formulation of claim 1 , wherein the rehydrated liposomes are suspended in a gel or solution suitable for direct administration to a tissue or tissue lumen.
8. The formulation of claim 7 , wherein the tacrolimus is present in the gel or solution in a concentration of 0.05 mg/ml to 2.5 mg/ml.
9. The formulation of claim 1 , wherein the liposomes comprise sphingomyelin.
10. A pre-liposomal lyophilized dry powder formulation which is capable of being rehydrated to form multilamellar metastable liposomes having a mean diameter of between one and 100 microns, inclusive, which comprise tacrolimus,
wherein, upon rehydration to form liposomes, the tacrolimus would become entrapped within the lipid forming the liposomes;
wherein, upon rehydration to form liposomes, the ratio of the volume enclosed by the liposomes at 25° C. relative to the volume enclosed by the liposomes following heating to a temperature that surpasses the gel-fluid phase transition of one or more lipids forming the liposomes is greater than 1.0;
wherein, upon rehydration to form liposomes, the tacrolimus is present in the dosage formulation in an amount ranging from between 20 to 50 mg; and
wherein the dry powder is prepared by a method comprising:
(a) dispersing the lipid forming the liposomes in a co-solvent system to create an isotropic monophasic solution;
(b) mixing the isotropic monophasic solution with the tacrolimus to form a pre-liposomal solution; and
(c) lyophilizing the pre-liposomal solution to produce a pre-liposomal lyophilized formulation.
11. A method comprising administering a dosage formulation of metastable liposomes to a tissue or tissue lumen of an individual, comprising:
(a) multilamellar metastable liposomes having a mean diameter of between one and 100 microns, inclusive, which comprise tacrolimus,
wherein the ratio of the volume enclosed by the liposomes at 25° C. relative to the volume enclosed by the liposomes following heating to a temperature that surpasses the gel-fluid phase transition of one or more lipids forming the liposomes is greater than 1.0;
wherein the tacrolimus is entrapped within the lipid forming the liposomes,
wherein the tacrolimus is present in the dosage formulation in an amount ranging from between 20 to 50 mg; and
wherein the liposomes are prepared by a method comprising:
(a) dispersing the lipid forming the liposomes in a co-solvent system to create an isotropic monophasic solution;
(b) mixing the isotropic monophasic solution with the tacrolimus to form a pre-liposomal solution;
(c) lyophilizing the pre-liposomal solution to produce a pre-liposomal lyophilized formulation; and
(d) rehydrating the pre-liposomal lyophilized formulation of step (c) to produce the liposomes.
12. The method of claim 11 , wherein the liposomes further comprise a prophylactic agent, a diagnostic agent, or a second therapeutic agent encapsulated within the liposomes.
13. The method of claim 11 , wherein step (d) entails suspending the liposomes in a gel or solution, by reconstitution in a pharmaceutically acceptable carrier, suitable for direct administration to the tissue or tissue lumen.
14. The method of claim 13 , wherein the tacrolimus is present in the gel or solution in a concentration of between 0.05 mg/ml to 2.5 mg/ml.
15. The method of claim 11 , wherein the formulation is administered via a cystoscope comprising an applicator selected from the group consisting of a spray device, gauze, roller, and sponge.
16. The method of claim 11 , wherein the liposomes comprise sphingomyelin.
17. The method of claim 11 , wherein the tacrolimus is for treatment of a bladder disease or disorder.
18. The method of claim 17 , wherein the formulation is administered via intravesical instillation into the bladder of the individual.
19. The method of claim 18 , wherein the bladder disease or disorder is selected from the group consisting of hemorrhagic cystitis, interstitial cystitis, and cancer.